Mirum Pharmaceuticals And Incyte Announce That Phase 2 Results From The PROGRESS Study Evaluating Zilurgisertib In Patients With Fibrodysplasia Ossificans Progressiva Will Be Presented At The Endocrine Society Annual Meeting, June 13-16

Loading news article.

Mirum Pharmaceuticals And Incyte Announce That Phase 2 Results From The PROGRESS Study Evaluating Zilurgisertib In Patients With Fibrodysplasia Ossificans Progressiva Will Be Presented At The Endocrine Society Annual Meeting, June 13-16 | WAPE

Mirum Pharmaceuticals And Incyte Announce That Phase 2 Results From The PROGRESS Study Evaluating Zilurgisertib In Patients With Fibrodysplasia Ossificans Progressiva Will Be Presented At The Endocrine Society Annual Meeting, June 13-16

Article summary

Related companies

Comments —